Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma by Robert, Caroline et al.








Long-term safety of pembrolizumab monotherapy and relationship with
clinical outcome: A landmark analysis in patients with advanced melanoma
Robert, Caroline ; Hwu, Wen-Jen ; Hamid, Omid ; Ribas, Antoni ; Weber, Jeffrey S ; Daud, Adil I ;
Hodi, F Stephen ; Wolchok, Jedd D ; Mitchell, Tara C ; Hersey, Peter ; Dronca, Roxana ; Joseph,
Richard W ; Boutros, Celine ; Min, Le ; Long, Georgina V ; Schachter, Jacob ; Puzanov, Igor ; Dummer,
Reinhard ; Lin, Jianxin ; Ibrahim, Nageatte ; Diede, Scott J ; Carlino, Matteo S ; Joshua, Anthony M
Abstract: Objective Long-term safety of pembrolizumab in melanoma was analyzed in KEYNOTE-001,
KEYNOTE-002, and KEYNOTE-006. Patients and methods Analysis involved patients who received
฀1 pembrolizumab dose. Lead-time bias was addressed via landmark analyses in patients who were
progression-free before day 147. Results Adverse events (AEs) were analyzed for 1567 patients (median
follow-up, 42.4 months). Most AEs were mild/moderate; grade 3/4 treatment-related AEs occurred
in 17.7% of patients. Two pembrolizumab-related deaths occurred. Any-grade immune-mediated AEs
(imAEs) occurred in 23.0%, most commonly hypothyroidism (9.1%), pneumonitis (3.3%), and hyperthy-
roidism (3.0%); grade 3/4 imAEs occurred in 6.9% of patients. Most imAEs occurred within 16 weeks
of treatment. In landmark analysis, patients who did (n = 79) versus did not (n = 384) develop imAEs
had similar objective response rates (ORRs) (64.6% versus 63.0%); median time to response (TTR), 5.6
months for both; median duration of response (DOR), 20.0 versus 25.3 months; median progression-free
survival (PFS), 17.0 versus 17.7 months; median overall survival (OS), not reached (NR) versus 43 months
(p = 0.1104). Patients who did (n = 17) versus did not (n = 62) receive systemic corticosteroids had
similar ORRs (70.6% vs. 62.9%) and median TTR (6.4 vs. 5.6 months) but numerically shorter median
PFS (9.9 vs. 17.0 months); median DOR, 14.2 months versus NR; median OS, NR for both. Conclusions
These results enhance the knowledge base for pembrolizumab in advanced melanoma, with no new toxi-
city signals after lengthy follow-up of a large population. In landmark analyses, pembrolizumab efficacy
was similar regardless of imAEs or systemic corticosteroid use. Clinical trial registry NCT01295827,
NCT01704287, NCT01866319.
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Abstract Objective: Long-term safety of pembrolizumab in melanoma was analyzed in
KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006.
Patients and methods: Analysis involved patients who received 1 pembrolizumab dose. Lead-
time bias was addressed via landmark analyses in patients who were progression-free before
day 147.
Results: Adverse events (AEs) were analyzed for 1567 patients (median follow-up, 42.4months).
Most AEs were mild/moderate; grade 3/4 treatment-related AEs occurred in 17.7% of patients.
Two pembrolizumab-related deaths occurred. Any-grade immune-mediated AEs (imAEs)
occurred in 23.0%, most commonly hypothyroidism (9.1%), pneumonitis (3.3%), and hyperthy-
roidism (3.0%); grade 3/4 imAEs occurred in 6.9% of patients. Most imAEs occurred within 16
weeks of treatment. In landmark analysis, patients who did (nZ 79) versus did not (nZ 384)
develop imAEs had similar objective response rates (ORRs) (64.6% versus 63.0%); median time
to response (TTR), 5.6 months for both; median duration of response (DOR), 20.0 versus 25.3
months; median progression-free survival (PFS), 17.0 versus 17.7 months; median overall sur-
vival (OS), not reached (NR) versus 43 months (pZ 0.1104). Patients who did (nZ 17) versus
did not (nZ 62) receive systemic corticosteroids had similarORRs (70.6%vs. 62.9%) andmedian
TTR(6.4vs.5.6months)butnumerically shortermedianPFS(9.9vs.17.0months);medianDOR,
14.2 months versus NR; median OS, NR for both.
Conclusions: These results enhance the knowledge base for pembrolizumab in advanced mela-
noma,with nonew toxicity signals after lengthy follow-up of a large population. In landmark an-
alyses, pembrolizumab efficacy was similar regardless of imAEs or systemic corticosteroid use.
Clinical trial registry: NCT01295827, NCT01704287, NCT01866319.
ª 2020TheAuthor(s). Published byElsevier Ltd. This is an open access article under theCCBY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The immune-checkpoint inhibitors pembrolizumab,
nivolumab, and ipilimumab have significantly improved
overall survival (OS) in patients with metastatic mela-
noma [1]. Pembrolizumab is approved for the treatmentof
various malignancies, including advanced melanoma [2].
Thesafetyandefficacyofpembrolizumabmonotherapy in
melanoma was established through three studies,
KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006
[3e6]. The phase Ib KEYNOTE-001 study included pa-
tients with melanoma irrespective of prior ipilimumab
therapy [3,7]. The phase II KEYNOTE-002 study
compared pembrolizumab with standard-of-care
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chemotherapy in ipilimumab-refractory melanoma [8].
The phase III KEYNOTE-006 study compared pem-
brolizumab with ipilimumab in ipilimumab-naive
advanced melanoma [5,9]. Across these trials, pem-
brolizumab induced robust and durable antitumor re-
sponses and had a favorable safety profile.
Immune-mediated adverse events (imAEs) have
occurred with programmed death 1 (PD-1) inhibitors,
including pembrolizumab [10]. Pembrolizumab is
generally associated with low-grade and manageable
AEs, including dermatologic, gastrointestinal, endo-
crine, hepatic, renal, and pulmonary toxicities [4,7e9].
This analysis examined the long-term safety of pem-
brolizumab monotherapy across KEYNOTE-001,
KEYNOTE-002, and KEYNOTE-006. In addition,
the relationship between imAE occurrence and efficacy
was examined. Potential correlations between imAEs
and clinical outcomes after checkpoint inhibition are
unclear, and many studies have not considered lead-time
bias that might give rise to misinterpretation of data
[11].
2. Material and methods
2.1. Patients
Pembrolizumab data from 3 trials were pooled (details
in Appendix). Follow-up was defined as time from
randomization to database cutoff. As the safety profile
of pembrolizumab has been shown to be similar across
dosing regimens, the data from all pembrolizumab dose
groups in KEYNOTE-001, KEYNOTE-002, and
KEYNOTE-006 were pooled [5,8,9].
2.2. Safety and efficacy assessments
Safety evaluations included treatment-related AEs
(TRAEs), time to onset and resolution of AEs, and use of
systemic corticosteroids to manage TRAEs or imAEs.
Adverse events were considered an imAE based on
mechanism of action and a prespecified list of terms pro-
vided by the sponsor (details in Appendix). AEs were
graded per the Common Terminology Criteria for
Adverse Events (version 4.0) [12]. Time to AE resolution
was defined as the longest time from onset to complete
resolution or improvement to baseline grade. Resolved
AEs were defined as events in which the outcome was
recorded as ‘recovered/resolved’ or ‘recovered/resolved
with sequelae’ based on the investigator’s discretion, and
an end date was specified. Because there were no specific
guidelines for resolution of AEs, endocrine AEs that were
managed with hormone supplements might have been
categorized as resolved or unresolved by different in-
vestigators. An exploratory analysis evaluated the rela-
tionship between imAE development and efficacy end-
points, objective response rate (ORR), time to response
(TTR), durationof response (DOR), andprogression-free
survival (PFS).AEsoccurringbefore thedateofPFSevent
were included. Tumor assessment was conducted at
baseline, followed by imaging every 12weeks. Byweek 21,
997 (63.6%) patients experienced disease progression and
107 (6.82%) patients died. To reduce lead-time bias, a
landmark analysis [13] was conducted of ORR, TTR,
DOR, and PFS by occurrence of imAEs (none vs. any) in
patients (n Z 463) still on therapy per protocol and
without progression before day 147 (week 21). The best
overall responses (BORs) before week 21 were not
considered, and BOR was re-evaluated at week 21. To
manage imAEs, systemic corticosteroids were allowed
(Appendix Table A1). To evaluate the potential impact of
AEmanagementonpembrolizumabefficacy,ORR,TTR,
DOR, PFS, andOSwere assessed in patients who did and
did not receive systemic corticosteroids. Tumor responses




Safety and efficacy were assessed in patients who
received 1 dose of pembrolizumab. ORR and 95%
confidence intervals (CIs) were estimated using the
Clopper-Pearson method; the difference in ORR among
subgroups and 95% CIs were estimated using the
Miettinen and Nurminen method; p values were one-
sided. TTR and DOR were assessed in patients with
confirmed complete or partial response. PFS and DOR
were estimated using the Kaplan-Meier method; asso-
ciated 95% CIs for median PFS were estimated using the
Greenwood formula. The hazard ratio (HR) for PFS
comparison was based on the Cox regression model,
with treatment as a covariate; p values were one-sided
and based on the log-rank test. SAS software, version
9.4 (Cary, NC), was used for all analyses.
3. Results
3.1. Patients
Overall, 1567 (616 women, 951 men) pembrolizumab-
treated patients with melanoma were included from
KEYNOTE-001 (nZ 655), KEYNOTE-002 (nZ 357),
and KEYNOTE-006 (n Z 555). Median age was 62.0
years (range, 15e94); 577 (36.8%) patients had elevated
lactate dehydrogenase (LDH) levels; 157 (10.0%) had
stable, previously treated brain metastases; and 44.6%
previously received ipilimumab therapy (Appendix
Table A2). Median treatment duration was 5.1 months
(range, 0.0e46.3); patients received a median of nine
doses of pembrolizumab (range, 1e91). At data cutoff
(KEYNOTE-001: September 18, 2015; KEYNOTE-002:
February 3, 2017; KEYNOTE-006: December 4, 2017),
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median follow-up was 42.4 months (range, 24.6e50.6).
Among patients who did (n Z 1265) versus did not
(n Z 302) experience a TRAE, baseline characteristics
were generally balanced; however, a greater proportion
of patients who had TRAEs had an Eastern Coopera-
tive Oncology Group performance score of 0 (69.0% vs.
49.7%), had normal LDH levels (65.8% vs. 44.7%), had
longer median treatment duration (7.7 vs. 2.1 months),
and received more pembrolizumab doses (median, 13 vs.
4) (Appendix Table A3).
3.2. Pooled safety analysis
3.2.1. Adverse events
3.2.1.1. Any-cause AEs and TRAEs. At data cutoff, 1546
(98.7%) patients had any-cause AEs of any grade and
787 (50.2%) had grade 3/4 AEs (Appendix Table A4). A
total of 165 (10.5%) patients experienced 1 AEs, most
commonly malignant neoplasm progression (n Z 111;
7.1%) and died subsequently. Any-grade TRAEs
occurred in 80.7% of patients (Appendix Table A5),
most commonly (15%) fatigue (32.5%), pruritus
(24.4%), rash (18.6%), and diarrhea (17.8%) (Appendix
Table A6). A total of 278 (17.7%) patients experienced
grade 3/4 TRAEs, most commonly colitis (1.5%),
diarrhea (1.4%), and fatigue (1.3%). Two deaths were
considered pembrolizumab-related (sepsis in one
patient in KEYNOTE-006 [9]; general physical health
deterioration in the setting of grade 3 diarrhea and
pneumonia in one patient [85 years] in KEYNOTE-
002 [4]). A total of 300 (19.1%) patients received
systemic corticosteroids for a TRAE, 1267 (80.9%) did
not. TRAEs led to discontinuation in 138 (8.8%)
patients; the most frequently reported (>1%) were
colitis and pneumonitis, each occurring in 18 (1.1%)
patients. Additionally, autoimmune hepatitis led to
discontinuation in 7 (0.4%) patients; fatigue and
arthralgia in 6 (0.4%) patients; and diarrhea in 4
(0.3%) patients.
3.2.1.2. imAEs: Incidence, onset, and resolution. Any-grade
imAEs occurred in 361 (23.0%) patients, most
commonly (1.0%) hypothyroidism (9.1%), pneumo-
nitis (3.3%), hyperthyroidism (3.0%), colitis (2.7%), skin
and subcutaneous disorders (1.8%), infusion reactions
(1.8%), hypophysitis (1.4%), hepatitis (1.2%), uveitis
(1.1%), and thyroiditis (1.0%) (Figure 1A). Grade 3/4
imAEs occurred in 108 (6.9%) patients. Median time
(in weeks) to onset and resolution of the most
common imAEs were hypothyroidism, 15.9 and 8.6;
pneumonitis, 36.0 and 8.1; hyperthyroidism, 7.3 and
6.1; colitis, 34.7 and 6.0; skin and subcutaneous
disorders, 41.1 and 3.1 (Figures 1B and C). Overall,
75% of imAEs were resolved at data cutoff. Most
imAEs (251 new imAEs in 196 [12.5%] patients)
occurred within 16 weeks of the first pembrolizumab
administration (Figure 2A). Within 160 weeks of
treatment initiation, 3 (0.7%) patients of 429 still
receiving study treatment developed three new imAE
events (Figure 2A). Median time (in weeks) to
resolution of the first imAEs treated with systemic
corticosteroids: pneumonitis, 7.5; colitis, 6.3;
hypophysitis, 9.0; hepatitis, 8.6; adrenal insufficiency,
2.9 (Figure 2B).
3.2.1.3. imAEs managed with systemic corticosteroids: Time to
resolution. Of 361 patients with imAEs, 156 (43.2%)
received systemic corticosteroids for treatment of an
imAE. Of the 202 any-grade imAEs that were managed
using systemic corticosteroids, 152 (75.2%) resolved,
with a median time to resolution of 6.4 weeks (range,
0.3e152.1). A total of 36 (23.1%) patients required a
second course of the same systemic corticosteroid or a
first dose of a new systemic corticosteroid. Of the 93
grade 3/4 imAEs that occurred in 87 (5.6%) patients and
managed using systemic corticosteroids, 75 (86%)
resolved with a median time to resolution of 5.1 weeks
(range, 0.4e152.1).
3.2.2. Impact of imAEs on clinical response, PFS, and OS
Of the 463 patients who were progression-free before
day 147 (week 21) with available data (291 were still on
study), 79 (17.1%) experienced imAEs before week 21
and 384 (82.9%) did not. ORR, median TTR, and me-
dian DOR were similar among those who had and had
not experienced any-grade imAEs (ORR, 64.6% vs
63.0%, p Z 0.3983; median TTR, 5.6 months each;
median DOR, 20.0 vs. 25.3 months, respectively) (Table
1).
Median PFS was similar among patients who had
and had not experienced any-grade imAEs (17.0 vs.
17.7 months; p Z 0.4522) (Table 2; Figure 3). Median
OS was not reached (NR) for patients who experienced
any-grade imAEs and was 43 months for those who
did not (p Z 0.1104). Three-year OS rates were 66.2%
and 59.4%, respectively. Grade 3/4 imAEs occurred in
10 of 463 (2.2%) patients included in the landmark
analysis; median OS was not significantly different
between these patients (NR) and those who did not
(n Z 453) experience grade 3/4 imAEs (43.0 months;
p Z 0.6472).
3.2.3. Impact of systemic corticosteroid use on clinical
response, PFS, and OS
In landmark analysis, 17 of 79 (21.5%) patients who
experienced imAEs received systemic corticosteroids for
the management of imAEs and 62 (78.5%) did not.
Among patients with imAEs, ORR and median TTR
were similar for patients who did and did not receive
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systemic corticosteroids (ORR, 70.6% vs. 62.9%,
p Z 0.2799; median TTR, 6.4 vs. 5.6 months, respec-
tively) (Table 1). Median DOR was 14.2 months (range,
0.0e14.2) for patients who did and NR for patients who
did not receive systemic corticosteroids. The percentage
of patients with responses lasting 12 months was
80.8% and 92.8%, respectively. Median PFS was
numerically shorter among patients who did versus did
not (9.9 vs. 17.0 months) receive systemic corticosteroids
for imAEs; however, the 95% CI for the HR was wide
(0.76e2.79) and associated with a large p value
(p Z 0.8692). Median OS was NR in both groups
(p Z 0.3799). Three-year OS rates were 70.1% and
64.7%, respectively (Table 2; Appendix Figure A1).
4. Discussion
This pooled analysis of KEYNOTE-001, KEYNOTE-
002, and KEYNOTE-006 is the most comprehensive
analysis of long-term pembrolizumab safety in advanced
melanoma. No new toxicity signals (AE type or inci-
dence) were identified. Notably, classification of AEs as
Fig. 1. Incidence of any-grade imAEsa occurring in at least one patient (N Z 1567) (A); median (range) time to onset (B) and resolution
(C) of any-grade imAEs (incidence >0%). imAEs, immune-mediated adverse events. aEndocrine AEs that were managed with hormone
supplements might have been categorized as resolved or unresolved by different investigators.
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immune-mediated was based on a prespecified AE list,
regardless of their suspected underlying immune mech-
anism. AEs that are classically not considered immune
mediateddsuch as fatigue, arthralgia, or pruritusdbut
might result from an immune reaction were therefore
excluded. Historically, definition of imAEs has varied
significantly, resulting in disparate data on the incidence
and severity of immune-related toxicities [15]. As more
data become available from patients treated with
checkpoint inhibitors, understanding of etiology of
imAEs will improve and allow better comparability
between studies.
Results show that most TRAEs, including imAEs
associated with pembrolizumab, were low grade. The
incidence of any-grade TRAEs, grade 3/4 TRAEs, and
TRAEs leading to discontinuation were similar to those
reported previously for pembrolizumab, as was the
imAE profile [6,8,9,16]. Most imAEs seen with pem-
brolizumab resolved without sequelae, except for
endocrine AEs such as adrenal insufficiency and
Fig. 2. First occurrence of imAEsa of any grade over time (A) and median (range) time to resolution of imAEs of any grade with cor-
ticosteroids (B). AEs, adverse events; imAEs, immune-mediated adverse events. aEndocrine AEs that were managed with hormone
supplements might have been categorized as resolved or unresolved by different investigators.
Table 1
Impact of imAEs and systemic corticosteroid use for imAEs on overall response, time to response, and duration of response to pembrolizumab
therapy in progression-free patients on pembrolizumab at week 21.
Any-grade imAEs Systemic corticosteroid for imAEs
Yes (n Z 79) No (n Z 384) Yes (n Z 17) No (n Z 62)
Overall response
No. of overall responses 51 242 12 39
ORR, % (95% CI) 64.6 (53.0e75.0) 63.0 (58.0e67.9) 70.6 (44.0e89.7) 62.9 (49.7e74.8)
Comparison of ORR Yes vs. no Yes vs. no
Estimated difference, % (95% CI)a 1.5 (10.5 to 12.5) 7.7 (18.9 to 29.0)
p valueb 0.3983 0.2799
Time to response
No. of responders 51 242 12 39
Median (range), months 5.6 (4.8e34.7) 5.6 (4.9e27.8) 6.4 (5.0e25.3) 5.6 (4.8e34.7)
DOR
Median (range), months 20.0 (0.0þ to 26.4þ) 25.3 (0.0þ to 34.3þ) 14.2 (0.0e14.2) NR (0.0þ to 26.4þ)
A total of 156 (10.0%) patients who received systemic corticosteroids, and 1411 (90.0%) patients who did not receive systemic corticosteroids to
manage imAEs of any grade were evaluated for tumor response.
AE, adverse event; CI, confidence interval; DOR, duration of response; imAE, immune-mediated adverse event; NR, not reached; ORR, objective
response rate.
a Based on Miettinen & Nurminen method.
b One-sided p value for testing. H0: difference in % Z 0 versus H1: difference in % > 0.
þ indicates the response duration is censored.
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hypophysitis, which often require long-term endocrine
therapy.
The association of tumor response and improved
relapse-free survival with the occurrence of imAEs has
been reported previously in melanoma treated with
immune-checkpoint inhibitors [17e20]. However, per-
forming such analyses without recognizing potential
guarantee-time bias, the time period a patient has to
remain free of the AEs to be included in the analysis,
might lead to misinterpretation because the occurrence
of the AE is linked to the duration of follow-up of each
patient [11]. In this analysis, we removed guarantee-time
bias by conducting a conditioned landmark analysis at
week 21 and considering the occurrence of imAEs in
patients without progression before day 147. This
revealed similar response characteristics and similar PFS
and OS among patients who did or did not experience
imAEs.
Successful management of imAEs is critical to
reducing sequelae and ensuring continued treatment
benefit [10,18]. Data on time to onset and resolution of
imAEs can inform clinicians of the similarities and dif-
ferences between therapies and assist in early recogni-
tion and management of these events. Mostly, the first
occurrence of imAEs associated with pembrolizumab
happened within the first 16 weeks, similar to what is
reported with nivolumab [17,18]. However, three (0.7%)
patients did experience the first occurrence of imAEs
later (at week 160 of treatment initiation). Thus, careful
monitoring of imAEs throughout treatment is
warranted.
Systemic corticosteroids may potentially mitigate
antitumor immune response [17,21,22]. In this analysis,
no significant differences were observed in efficacy
among patients who received and did not receive sys-
temic corticosteroids to manage imAEs. A finding
similar to that of other studies of checkpoint inhibitors
which have reported that systemic corticosteroids did
not negatively affect antitumor responses [17,21,22].
While these results suggest that systemic corticosteroids
do not impair the antitumor activity of checkpoint in-
hibitors, a caveat could be the masking of the effect of
corticosteroids on PD-1 efficacy because patients
requiring systemic corticosteroids may also be respon-
sive to anti-PD-1 therapy. Another parameter that may
influence the effect of corticosteroids on PD-1 efficacy in
the current analysis is the dose and duration of corti-
costeroids. The immunosuppressive effects of cortico-
steroids are dose-dependent, with higher doses leading
to greater immunosuppressive effects [23]. In the current
analysis, systemic corticosteroid use varied in dose and
duration among the 156 patients who received cortico-
steroids. Therefore, current results should be interpreted
with caution.
Limitations of this analysis include lack of multi-
plicity adjustments for hypothesis testing of association
between imAE occurrence or systemic corticosteroid use
and efficacy, and the choice of an appropriate landmark.
Ideally, one chooses a landmark at a time when all of the
classification events (imAEs) and none of the outcome
events (progression) have occurred [24]. For this anal-
ysis, setting the landmark at week 12 was considered too
soon because those having an imAE after week 12 would
be classified as having “no imAE” at week 12. Setting
the landmark at week 26 (or later) was considered too
late because patients who already had experienced pro-
gression would have been excluded. Week 21 was
thought to balance the goal of maximizing the number
of patients having imAE before the landmark, while
minimizing the number of patients having progression
before the landmark. Additional limitations include the
small subgroup size of patients in the landmark analysis
Table 2
Impact of imAEs and systemic corticosteroid use for imAEs on PFS and OS in patients on pembrolizumab therapy at week 21.
Any-grade imAEs Systemic corticosteroid for imAEs
Yes (n Z 79) No (n Z 384) Yes (n Z 17) No (n Z 62)
PFSa
No. of events 51 227 12 39
Median, months (95% CI) 17.0 (12.1e23.6) 17.7 (15.4e20.1) 9.9 (6.8e23.6) 17.0 (13.6e25.8)
Comparison of PFS Yes vs. no Yes vs. no
HR (95% CI)b 0.98 (0.72e1.33) 1.45 (0.76e2.79)
p valuec 0.4522 0.8692
OSa
No. of events 26 154 5 21
Median, months (95% CI) NR (38.2eNR) 43.0 (37.9eNR) NR (13.8eNR) NR (34.3eNR)
Comparison of OS Yes vs no Yes vs no
HR (95% CI)b 0.77 (0.51e1.17) 0.86 (0.32e2.28)
p valuec 0.1104 0.3799
AE, adverse event; CI, confidence interval; HR, hazard ratio; imAEs, immune-mediated adverse events; NR, not reached; ORR, objective response
rate; OS, overall survival; PFS, progression-free survival.
a From product-limit (Kaplan-Meier) method for censored data.
b Based on Cox regression model with treatment as a covariate.
c One-sided p value based on log-rank test.
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whereby of 79 patients who experienced imAEs, only 17
received systemic corticosteroids to manage imAEs. The
sample size for this subgroup may be considered insuf-
ficient to accurately assess the impact of corticosteroid
treatment on pembrolizumab efficacy.
Potential sources of bias include investigator discre-
tion in assessment of AE as treatment-related and dif-
ferences in baseline characteristics between patients who
had versus had not experienced imAEs. Data pooling
from three studies could also be considered a limitation
due to differences in patient populations. However,
KEYNOTE-001, KEYNOTE-002, and KEYNOTE-006
had similar eligibility criteria. This population is there-
fore likely to be more homogeneous and have more
complete data collection than that of a real-world
analysis, the only other study type that would include
such large patient numbers.
Results of this large pooled analysis have demon-
strated the long-term safety profile of pembrolizumab
monotherapy in advanced melanoma. TRAEs and
imAEs were primarily mild to moderate, and the efficacy
of pembrolizumab was similar regardless of the occur-
rence of imAEs or the use of systemic corticosteroids for
management of imAEs in the landmark analysis. These
results further enhance understanding of pem-
brolizumab safety for the treatment of advanced/meta-
static melanoma.
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